RxDoctor Payments Data

Avinash Persad, DO

Family Medicine · Coral Springs, FLNPI 1528453438

Payments from drug & device makers

$888in general payments, 2019–2025

Across 40 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$221
  • Lilly USA, LLC$209
  • Novo Nordisk$181
  • AstraZeneca$166
  • Johnson & Johnson$59
  • Pfizer$20
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$88299%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences8$221
Lilly USA, LLC11$209
Novo Nordisk10$181
AstraZeneca7$166
Johnson & Johnson1$59
Pfizer1$20
Amgen1$19
AbbVie1$13

How this compares

$888 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$38,610
Medicare patients
112
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide80$85,382
FarxigaDapagliflozin Propanediol79$65,414
Trijardy XrEmpaglifloz/Linaglip/Metformin38$51,877
JardianceEmpagliflozin48$51,147
JanuviaSitagliptin Phosphate29$37,459
EliquisApixaban20$30,189
TradjentaLinagliptin21$29,600
Synjardy XrEmpagliflozin/Metformin Hcl18$25,633
OzempicSemaglutide24$21,945
Janumet XrSitagliptin Phos/Metformin Hcl21$16,570
JanumetSitagliptin Phos/Metformin Hcl14$14,014
Repatha SureclickEvolocumab15$9,399
Rosuvastatin Calcium292$5,558
Tresiba Flextouch U-100Insulin Degludec11$5,441
Breo ElliptaFluticasone/Vilanterol12$4,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$209$85,38280 claims
AstraZenecaFarxiga$166$65,41479 claims
PfizerEliquis$20$30,18920 claims
Novo NordiskOzempic$181$21,94524 claims
AbbVieSynthroid$13$1,31315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Coral Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →